A carregar...
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
BACKGROUND: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids or immunoglobulins. METHODS: A cost-consequence model was developed to evaluate...
Na minha lista:
| Publicado no: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6219311/ https://ncbi.nlm.nih.gov/pubmed/30464563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S177324 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|